Biogen Message Board - Msg: 5584566

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen

BIIB 175.32

+4.2%

Nov 21 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Hong-Lee Yu who wrote (707)	8/25/1998 2:32:00 PM
From: Harold Engstrom	Read Replies (1) of 1686

Hong-Lee Yu, think you are right. 3000 new patients in the US this quarter almost seems like a done deal if the H&Q statement is correct. If IMS data shows over 1,100 new patients just last week, and IMS data does not account for all sales channels, then we are half way there in a week. Europe growth should slow during August, but sales there should grow by 2,000 patients easily. Would not be surprised to see some extremely healthy numbers put up during the 1st Q conference call. With Avonex revenues continuing to grow 15% quarter over quarter, Biogen's finances are looking particularly excellent. Cash should grow by at least $50MM this quarter. Let's hope Biogen finds some uses for it - sure hate seeing my best investments scooped up by big pharma before they can realize their potential.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next